Gladstone Institutional Advisory’s DexCom DXCM Stock Holding History

Gladstone Institutional Advisory’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-2,009	Closed	-$279K	–	671
2024 Q1	$279K	Sell	2,009 -263	-12%	-$33.1K	0.02%	547
2023 Q4	$282K	Sell	2,272 -4,030	-64%	-$412K	0.02%	537
2023 Q3	$588K	Sell	6,302 -35,789	-85%	-$4.03M	0.04%	358
2023 Q2	$5.41M	Buy	+42,091	New	+$5.09M	0.33%	82
2023 Q1	–	Sell	-6,507	Closed	-$737K	–	669
2022 Q4	$737K	Buy	+6,507	New	+$714K	0.05%	329
2022 Q1	–	Sell	-13,552	Closed	-$1.82M	–	714
2021 Q4	$1.82M	Buy	13,552 +2,020	+18%	+$290K	0.14%	192
2021 Q3	$1.58M	Buy	+11,532	New	+$1.45M	0.15%	173
2020 Q3	–	Sell	-4,156	Closed	-$421K	–	278
2020 Q2	$421K	Buy	4,156 +144	+4%	+$12.9K	0.11%	143
2020 Q1	$270K	Buy	+4,012	New	+$250K	0.07%	204

Other funds holding DXCM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Gladstone Institutional Advisory's DXCM Position: Q2 2024 in Review

Gladstone Institutional Advisory sold out of DexCom (DXCM) in Q2 2024, closing a stake of 2,009 shares — an estimated $279K sold.

Gladstone Institutional Advisory first reported a position in DXCM in Q1 2020 and held it in 9 quarters. The position peaked at $5.41M in Q2 2023. 999 funds tracked by Wall St. Rank hold DXCM as of Q2 2024.

Gladstone Institutional Advisory reported no remaining DexCom position as of Q2 2024 after selling out during the quarter.
Gladstone Institutional Advisory sold 2,009 DexCom shares in Q2 2024, an estimated $279K.
Gladstone Institutional Advisory first reported a position in DexCom in Q1 2020 and held it in 9 quarters.
Gladstone Institutional Advisory's DexCom position peaked at $5.41M in Q2 2023.
999 funds tracked by Wall St. Rank held DexCom as of Q2 2024.

Based on Gladstone Institutional Advisory's 13F filing for Q2 2024, filed 2 Aug 2024.